Skip to main content
Top
Published in: Advances in Therapy 1/2019

Open Access 01-01-2019 | Review

Recognising Lung Cancer in Primary Care

Authors: Stephen H. Bradley, Martyn P. T. Kennedy, Richard D. Neal

Published in: Advances in Therapy | Issue 1/2019

Login to get access

Abstract

Significant advances in the management of both early and advanced stage lung cancer have not yet led to the scale of improved outcomes which have been achieved in other cancers over the last 40 years. Diagnosis of lung cancer at the earliest stage of disease is strongly associated with improved survival. Therefore, although recent advances in oncology may herald breakthroughs in effective treatment, achieving early diagnosis will remain crucial to obtaining optimal outcomes. This is challenging, as most lung cancer symptoms are non-specific or are common respiratory symptoms which usually represent benign disease. Identification of patients at risk of lung cancer who require further investigation is an important responsibility for general practitioners (GPs). Diagnosis has historically relied upon plain chest X-ray (CXR), organised in response to symptoms. The sensitivity of this modality, however, compares unfavourably with that of computed tomography (CT). In some jurisdictions screening high-risk individuals with low dose CT (LDCT) is now recommended. However uptake remains low and the eligibility for screening programmes is restricted. Therefore, even if screening is widely adopted, most patients will continue to be diagnosed after presenting with symptoms. Achieving early diagnosis requires GPs to maintain an appropriate level of suspicion and readiness to investigate in high-risk patients or those with non-resolving symptoms. This article discusses the early detection of lung cancer from a primary care perspective. We outline risk factors and epidemiology, the role of screening and offer guidance on the recognition of symptomatic presentation and the investigation and referral of suspected lung cancer.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRef
8.
go back to reference Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74.CrossRef Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74.CrossRef
9.
go back to reference Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.CrossRef Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.CrossRef
10.
go back to reference Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.CrossRef Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.CrossRef
11.
go back to reference Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–9.CrossRef Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–9.CrossRef
13.
go back to reference Hamilton W. Five misconceptions in cancer diagnosis. Br J Gen Pract. 2009;59(563):441–7.CrossRef Hamilton W. Five misconceptions in cancer diagnosis. Br J Gen Pract. 2009;59(563):441–7.CrossRef
14.
go back to reference Demagny L, Holtedahl K, Bachimont J, Thorsen T, Letourmy A, Bungener M. General practitioners’ role in cancer care: a French-Norwegian study. BMC Res Notes. 2009;2(1):200.CrossRef Demagny L, Holtedahl K, Bachimont J, Thorsen T, Letourmy A, Bungener M. General practitioners’ role in cancer care: a French-Norwegian study. BMC Res Notes. 2009;2(1):200.CrossRef
15.
go back to reference Tørring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer. 2013;49(9):2187–98.CrossRef Tørring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer. 2013;49(9):2187–98.CrossRef
16.
go back to reference Ewing M, Naredi P, Nemes S, Zhang C, Månsson J. Increased consultation frequency in primary care, a risk marker for cancer: a case–control study. Scand J Prim Health Care. 2016;34(2):205–12.CrossRef Ewing M, Naredi P, Nemes S, Zhang C, Månsson J. Increased consultation frequency in primary care, a risk marker for cancer: a case–control study. Scand J Prim Health Care. 2016;34(2):205–12.CrossRef
17.
go back to reference Iyen-Omofoman B, Tata LJ, Baldwin DR, Smith CJ, Hubbard RB. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax. 2013;68(5):451–9.CrossRef Iyen-Omofoman B, Tata LJ, Baldwin DR, Smith CJ, Hubbard RB. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax. 2013;68(5):451–9.CrossRef
18.
go back to reference Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract. 2018;68(666):e63–72.CrossRef Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract. 2018;68(666):e63–72.CrossRef
19.
go back to reference Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer. 2013;108:686.CrossRef Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer. 2013;108:686.CrossRef
20.
go back to reference McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112 (Suppl 1):S108–15.CrossRef McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112 (Suppl 1):S108–15.CrossRef
23.
go back to reference Vedsted P, Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. Br J Gen Pract. 2011;61(589):e508–12.CrossRef Vedsted P, Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. Br J Gen Pract. 2011;61(589):e508–12.CrossRef
24.
go back to reference Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130–41.CrossRef Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130–41.CrossRef
25.
go back to reference Villeneuve P, Mao Y. Lifetime probability of developing lung cancer. Can J Public Health. 1994;85(6):385–8.PubMed Villeneuve P, Mao Y. Lifetime probability of developing lung cancer. Can J Public Health. 1994;85(6):385–8.PubMed
26.
go back to reference Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomark Prev. 2006;15(3):517–23.CrossRef Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomark Prev. 2006;15(3):517–23.CrossRef
27.
go back to reference Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer. 2005;92:426.CrossRef Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer. 2005;92:426.CrossRef
28.
go back to reference Peto J. That lung cancer incidence falls in ex-smokers: misconceptions 2. Br J Cancer. 2011;104(3):389.CrossRef Peto J. That lung cancer incidence falls in ex-smokers: misconceptions 2. Br J Cancer. 2011;104(3):389.CrossRef
29.
go back to reference Pelosof L, Ahn C, Gao A, et al. Proportion of never-smoker non-small cell lung cancer patients at three diverse institutions. J Natl Cancer Inst. 2017;109(7):295.CrossRef Pelosof L, Ahn C, Gao A, et al. Proportion of never-smoker non-small cell lung cancer patients at three diverse institutions. J Natl Cancer Inst. 2017;109(7):295.CrossRef
30.
go back to reference Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163(12):1475–80.CrossRef Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163(12):1475–80.CrossRef
31.
go back to reference Skillrud DM, Offord KP, Miller R. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med. 1986;105(4):503–7.CrossRef Skillrud DM, Offord KP, Miller R. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med. 1986;105(4):503–7.CrossRef
32.
go back to reference Kiri VA, Soriano JB, Visick G, Fabbri LM. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2009;19:57.CrossRef Kiri VA, Soriano JB, Visick G, Fabbri LM. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2009;19:57.CrossRef
33.
go back to reference Young RP, Duan F, Chiles C, et al. Airflow limitation and histology shift in the National Lung Screening Trial. The NLST-ACRIN cohort substudy. Am J Respir Crit Care Med. 2015;192(9):1060–7.CrossRef Young RP, Duan F, Chiles C, et al. Airflow limitation and histology shift in the National Lung Screening Trial. The NLST-ACRIN cohort substudy. Am J Respir Crit Care Med. 2015;192(9):1060–7.CrossRef
34.
go back to reference Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):121–7.CrossRef Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):121–7.CrossRef
35.
go back to reference McCormack V, Peto J, Byrnes G, Straif K, Boffetta P. Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer. 2012;106:575.CrossRef McCormack V, Peto J, Byrnes G, Straif K, Boffetta P. Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer. 2012;106:575.CrossRef
36.
go back to reference Brown T, Darnton A, Fortunato L, Rushton L. Occupational cancer in Britain. Br J Cancer. 2012;107:S56.CrossRef Brown T, Darnton A, Fortunato L, Rushton L. Occupational cancer in Britain. Br J Cancer. 2012;107:S56.CrossRef
39.
go back to reference Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.CrossRef Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.CrossRef
40.
go back to reference Schwartz AG, Ruckdeschel JC. Familial lung cancer. Am J Respir Crit Care Med. 2006;173(1):16–22.CrossRef Schwartz AG, Ruckdeschel JC. Familial lung cancer. Am J Respir Crit Care Med. 2006;173(1):16–22.CrossRef
41.
go back to reference Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48(13):1957–68.CrossRef Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48(13):1957–68.CrossRef
42.
go back to reference Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T. Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol. 2008;38(8):571–6.CrossRef Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T. Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol. 2008;38(8):571–6.CrossRef
44.
go back to reference Hamilton W. Towards earlier diagnosis of cancer in primary care: a population-based case-control study of colorectal, lung and prostate cancer. MD thesis, Bristol. 2005. Hamilton W. Towards earlier diagnosis of cancer in primary care: a population-based case-control study of colorectal, lung and prostate cancer. MD thesis, Bristol. 2005.
45.
go back to reference Shim J, Brindle L, Simon M, George S. A systematic review of symptomatic diagnosis of lung cancer. Fam Pract. 2014;31(2):137–48.CrossRef Shim J, Brindle L, Simon M, George S. A systematic review of symptomatic diagnosis of lung cancer. Fam Pract. 2014;31(2):137–48.CrossRef
46.
go back to reference Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059–65.CrossRef Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059–65.CrossRef
47.
go back to reference Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015;112:S6.CrossRef Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015;112:S6.CrossRef
49.
go back to reference Beckett P, Tata LJ, Hubbard RB. Risk factors and survival outcome for non-elective referral in non-small cell lung cancer patients—analysis based on the National Lung Cancer Audit. Lung Cancer. 2014;83(3):396–400.CrossRef Beckett P, Tata LJ, Hubbard RB. Risk factors and survival outcome for non-elective referral in non-small cell lung cancer patients—analysis based on the National Lung Cancer Audit. Lung Cancer. 2014;83(3):396–400.CrossRef
50.
go back to reference Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake MD. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br J Cancer. 2014;112:207.CrossRef Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake MD. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br J Cancer. 2014;112:207.CrossRef
51.
go back to reference Kennedy MPT, Cheyne L, Darby M, et al. Lung cancer stage-shift following a symptom awareness campaign. Thorax. 2018;73(12):1128–36.CrossRef Kennedy MPT, Cheyne L, Darby M, et al. Lung cancer stage-shift following a symptom awareness campaign. Thorax. 2018;73(12):1128–36.CrossRef
52.
go back to reference Peake M. National cancer registration and analysis service. Be clear on cancer: regional and national lung cancer awareness campaigns 2011 to 2014. Final evaluation results—executive headlines. London: Public Health England. 2018. Available ncin.org.uk/view?rid=3632. Accessed 27 Nov 2018. Peake M. National cancer registration and analysis service. Be clear on cancer: regional and national lung cancer awareness campaigns 2011 to 2014. Final evaluation results—executive headlines. London: Public Health England. 2018. Available ncin.​org.​uk/​view?​rid=​3632. Accessed 27 Nov 2018.
53.
go back to reference Emery JD, Gray V, Walter FM, et al. The improving rural cancer outcomes trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia. Br J Cancer. 2017;117:1459.CrossRef Emery JD, Gray V, Walter FM, et al. The improving rural cancer outcomes trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia. Br J Cancer. 2017;117:1459.CrossRef
54.
go back to reference Hamilton W. The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. Br J Cancer. 2009;101:S80.CrossRef Hamilton W. The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. Br J Cancer. 2009;101:S80.CrossRef
55.
go back to reference Hamilton W, Green T, Martins T, Elliott K, Rubin G, Macleod U. Evaluation of risk assessment tools for suspected cancer in general practice: a cohort study. Br J Gen Pract. 2013;63(606):e30–6.CrossRef Hamilton W, Green T, Martins T, Elliott K, Rubin G, Macleod U. Evaluation of risk assessment tools for suspected cancer in general practice: a cohort study. Br J Gen Pract. 2013;63(606):e30–6.CrossRef
56.
go back to reference Hippisley-Cox J, Coupland C. Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2011;61(592):e715–23.CrossRef Hippisley-Cox J, Coupland C. Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2011;61(592):e715–23.CrossRef
57.
58.
go back to reference Hamilton W. Cancer diagnosis in primary care. Br J Gen Pract. 2010;60(571):121–8.CrossRef Hamilton W. Cancer diagnosis in primary care. Br J Gen Pract. 2010;60(571):121–8.CrossRef
59.
go back to reference Barraclough K. New NICE guidance on referral for cancer. BMJ. 2015;351:h3640.CrossRef Barraclough K. New NICE guidance on referral for cancer. BMJ. 2015;351:h3640.CrossRef
60.
go back to reference Nicholson BD, Mant D, Bankhead C. Can safety-netting improve cancer detection in patients with vague symptoms? BMJ. 2016;355:i5515. Nicholson BD, Mant D, Bankhead C. Can safety-netting improve cancer detection in patients with vague symptoms? BMJ. 2016;355:i5515.
61.
go back to reference Mitchell ED, Rubin G, Macleod U. Understanding diagnosis of lung cancer in primary care: qualitative synthesis of significant event audit reports. Br J Gen Pract. 2013;63(606):e37–46.CrossRef Mitchell ED, Rubin G, Macleod U. Understanding diagnosis of lung cancer in primary care: qualitative synthesis of significant event audit reports. Br J Gen Pract. 2013;63(606):e37–46.CrossRef
64.
go back to reference Stapley S, Sharp D, Hamilton W. Negative chest X-rays in primary care patients with lung cancer. Br J Gen Pract. 2006;56(529):570–3.PubMedPubMedCentral Stapley S, Sharp D, Hamilton W. Negative chest X-rays in primary care patients with lung cancer. Br J Gen Pract. 2006;56(529):570–3.PubMedPubMedCentral
65.
go back to reference Fernandez V, Alonso JL, Munuera L, et al. Analysis of lung cancer cases diagnosed in an internal medicine department: from January 2001 to September 2006. An Sist Sanit Navar. 2007;30(3):353–62.CrossRef Fernandez V, Alonso JL, Munuera L, et al. Analysis of lung cancer cases diagnosed in an internal medicine department: from January 2001 to September 2006. An Sist Sanit Navar. 2007;30(3):353–62.CrossRef
66.
go back to reference Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56(532):863–8.PubMedPubMedCentral Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56(532):863–8.PubMedPubMedCentral
68.
go back to reference Athey VL, Suckling RJ, Tod AM, Walters SJ, Rogers TK. Early diagnosis of lung cancer: evaluation of a community-based social marketing intervention. Thorax. 2012;67(5):412–7. Athey VL, Suckling RJ, Tod AM, Walters SJ, Rogers TK. Early diagnosis of lung cancer: evaluation of a community-based social marketing intervention. Thorax. 2012;67(5):412–7.
69.
go back to reference Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):1–55.CrossRef Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):1–55.CrossRef
70.
go back to reference Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. 2011;171(13):1193–8.CrossRef Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. 2011;171(13):1193–8.CrossRef
71.
go back to reference National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.CrossRef National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.CrossRef
75.
go back to reference Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277–84.CrossRef Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277–84.CrossRef
76.
go back to reference Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the national lung screening trial. Am J Roentgenol. 2011;197(5):1165–9.CrossRef Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the national lung screening trial. Am J Roentgenol. 2011;197(5):1165–9.CrossRef
78.
go back to reference Guldbrandt LM, Rasmussen RR, Ramussen F, Vedsted P. Implementing direct access to low-dose computed tomography in general practice-method, adaption and outcome. PLoS One. 2014;9(11):1–9.CrossRef Guldbrandt LM, Rasmussen RR, Ramussen F, Vedsted P. Implementing direct access to low-dose computed tomography in general practice-method, adaption and outcome. PLoS One. 2014;9(11):1–9.CrossRef
79.
go back to reference Arooj P, Bredin E, Henry MT, et al. Bronchoscopy in the investigation of outpatients with hemoptysis at a lung cancer clinic. Respir Med. 2018;139:1–5.CrossRef Arooj P, Bredin E, Henry MT, et al. Bronchoscopy in the investigation of outpatients with hemoptysis at a lung cancer clinic. Respir Med. 2018;139:1–5.CrossRef
80.
go back to reference Kennedy MP, Arooj P, Henry MT. Bronchoscopy is not required in patients being investigated for hemoptysis at a rapid access cancer clinic with normal CT scan. Chest. 2018;154(2):465–6.CrossRef Kennedy MP, Arooj P, Henry MT. Bronchoscopy is not required in patients being investigated for hemoptysis at a rapid access cancer clinic with normal CT scan. Chest. 2018;154(2):465–6.CrossRef
81.
go back to reference Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality. The prostate, lung, colorectal, and ovarian (PLCO) randomized trial. J Am Med Assoc. 2011;306(17):1865–73.CrossRef Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality. The prostate, lung, colorectal, and ovarian (PLCO) randomized trial. J Am Med Assoc. 2011;306(17):1865–73.CrossRef
82.
go back to reference National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef
83.
go back to reference Moyer VA. On behalf of the USPSTF. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–8.CrossRef Moyer VA. On behalf of the USPSTF. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–8.CrossRef
84.
go back to reference Pham D, Bhandari S, Oechsli M, Pinkston CM, Kloecker GH. Lung cancer screening rates: data from the lung cancer screening registry. J Clin Oncol. 2018;36(no. 15_suppl):6504. Pham D, Bhandari S, Oechsli M, Pinkston CM, Kloecker GH. Lung cancer screening rates: data from the lung cancer screening registry. J Clin Oncol. 2018;36(no. 15_suppl):6504.
85.
go back to reference Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278–81.CrossRef Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278–81.CrossRef
86.
go back to reference Baldwin DR, ten Haaf K, Rawlinson J, Callister MEJ. Low dose CT screening for lung cancer. BMJ. 2017;359:j5742. Baldwin DR, ten Haaf K, Rawlinson J, Callister MEJ. Low dose CT screening for lung cancer. BMJ. 2017;359:j5742.
87.
go back to reference Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–66.CrossRef Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–66.CrossRef
88.
go back to reference Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54(2):177–84.CrossRef Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54(2):177–84.CrossRef
89.
go back to reference Rampinelli C, De Marco P, Origgi D, et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ. 2017;356:j347.CrossRef Rampinelli C, De Marco P, Origgi D, et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ. 2017;356:j347.CrossRef
90.
go back to reference Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–29.CrossRef Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–29.CrossRef
91.
go back to reference Ruparel M, Quaife SL, Navani N, Wardle J, Janes SM, Baldwin DR. Pulmonary nodules and CT screening: the past, present and future. Thorax. 2016;71(4):367–75.CrossRef Ruparel M, Quaife SL, Navani N, Wardle J, Janes SM, Baldwin DR. Pulmonary nodules and CT screening: the past, present and future. Thorax. 2016;71(4):367–75.CrossRef
92.
go back to reference Bach PB. Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax. 2008;63(4):298–300.CrossRef Bach PB. Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax. 2008;63(4):298–300.CrossRef
93.
go back to reference ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Commun Health. 2015;69(11):1035–9.CrossRef ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Commun Health. 2015;69(11):1035–9.CrossRef
94.
go back to reference Heleno B, Siersma V, Brodersen J. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening: a secondary analysis of the Danish lung cancer screening trial. JAMA Intern Med. 2018;178(10):1420–2.CrossRef Heleno B, Siersma V, Brodersen J. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening: a secondary analysis of the Danish lung cancer screening trial. JAMA Intern Med. 2018;178(10):1420–2.CrossRef
95.
go back to reference Brenner AT, Malo TL, Margolis M, et al. Evaluating shared decision making for lung cancer screening. JAMA Intern Med. 2018;178(10):1311–6.CrossRef Brenner AT, Malo TL, Margolis M, et al. Evaluating shared decision making for lung cancer screening. JAMA Intern Med. 2018;178(10):1311–6.CrossRef
96.
go back to reference Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19(3):154–6.CrossRef Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19(3):154–6.CrossRef
97.
go back to reference Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2007;98:270.CrossRef Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2007;98:270.CrossRef
98.
go back to reference Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36.CrossRef Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36.CrossRef
Metadata
Title
Recognising Lung Cancer in Primary Care
Authors
Stephen H. Bradley
Martyn P. T. Kennedy
Richard D. Neal
Publication date
01-01-2019
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2019
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-018-0843-5

Other articles of this Issue 1/2019

Advances in Therapy 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.